DBV Technologies Tech Stack

Clinical-stage biotech developing skin-patch immunotherapy for food allergies

Biotechnology Research Châtillon, France 51–200 employees Public Company

DBV Technologies is a public clinical-stage biotech founded by pediatricians focused on epicutaneous immunotherapy—a method of retraining the immune system through the skin. The company's tech stack (Excel, SAS, JMP, R, Python) and active projects reveal a heavy emphasis on regulatory compliance, pharmacovigilance, and clinical data management rather than computational drug discovery, reflecting the reality of a late-stage clinical program approaching product launch. Leadership-heavy hiring (9 directors on the current roster) and pain points around public company reporting and regulatory documentation signal a company scaling post-IPO compliance and quality infrastructure.

Tech Stack 10 technologies

Core StackSalesforce SAS Python Dynamics 365 Excel Microsoft Project JMP R Microsoft Office Word

What DBV Technologies Is Building

◆Challenges

Streamlining compilation workflows
Fraud and abuse in healthcare
Managing 3pl performance
Public company reporting obligations
Unmet medical need
Regulatory documentation compliance
Cross-functional project coordination
Project kpi tracking
Managing global compliance program
Ensuring regulatory compliance across functions

▲Active Projects

Viaskin peanut patch launch
Data science for pharmacovigilance integration
Global data protection program
Clinical database design and maintenance
Sas program development for data checks
Rapid-cycle promotional research
Omnichannel support and communication infrastructure
Transparency and disclosure programs
Risk-based monitoring and auditing activities
Compliance program design and implementation

Hiring Activity

Steady20 roles · 7 in 30d

Department

Legal

Research

Healthcare

Marketing

Regulatory

Biometrics

Engineering

Finance

Seniority

Director

Manager

Senior

Mid

Notable leadership hires: Compliance Director, Project Director

Company intelligence

Find more companies like DBV Technologies by tech stack, pain points and active projects

Get started free

About DBV Technologies

DBV Technologies develops Viaskin, an epicutaneous immunotherapy platform designed to treat immunologic diseases by delivering allergen through the skin. The company's immediate focus is advancing a peanut allergy treatment toward regulatory approval; longer-term ambitions include expanding into inflammatory and autoimmune diseases. With 51–200 employees based in Châtillon, France, and active hiring in France and the United States, the organization operates across clinical, regulatory, quality, and commercial functions typical of a public biopharmaceutical company in late-stage development. Current operational priorities center on clinical database integrity, pharmacovigilance systems, and the compliance infrastructure required of a public company.

HeadquartersChâtillon, France

Company Size51–200 employees

Hiring MarketsFrance, United States

Frequently Asked Questions

What is DBV Technologies working on?

Primary focus: Viaskin peanut patch launch and associated clinical database design. Secondary projects: pharmacovigilance data integration, regulatory compliance program design, risk-based monitoring, and omnichannel patient communication infrastructure.

Where is DBV Technologies headquartered?

Châtillon, France. The company is actively hiring in France and the United States, with current open roles spanning legal, research, regulatory, and healthcare functions.

What tech does DBV Technologies use?

Primary stack: Excel, SAS, JMP, R, Python, Salesforce, and Microsoft Office. Tech reflects clinical operations (SAS/JMP for statistical analysis) and regulatory workflows (Salesforce for CRM, Dynamics 365 for ERP).